PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil

Immune checkpoint blockade (ICB) agents are prominent immunotherapies for the treatment of advanced melanoma. However, they fail to promote any durable clinical benefit in a large cohort of patients. This study assessed clinical and molecular predictors of ICB response and survival in advanced melan...

Descripción completa

Detalles Bibliográficos
Autores principales: Sorroche, Bruna Pereira, Teixeira, Renan de Jesus, Pereira, Caio Augusto Dantas, Santana, Iara Viana Vidigal, Vujanovic, Lazar, Vazquez, Vinicius de Lima, Arantes, Lidia Maria Rebolho Batista
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047789/
https://www.ncbi.nlm.nih.gov/pubmed/36980349
http://dx.doi.org/10.3390/diagnostics13061041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047789/
https://www.ncbi.nlm.nih.gov/pubmed/36980349
http://dx.doi.org/10.3390/diagnostics13061041

Ejemplares similares